Clinical Trial: Single-center, single-arm clinical study of the efficacy of orelabrutinib and lenalidomide (O-R regimen) in maintenance therapy in patients with highly aggressive B cell lymphoma (China)

Posted On: 2026-10-28

China, Oct. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Single-center, single-arm clinical study of the efficacy of orelabrutinib and lenalidomide (O-R regimen) in maintenance therapy in patients with highly aggressive B cell lymphoma'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600135230

Registration Time: 2026/10/27

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Zhejiang University School of Medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=164248

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Single-center, single-arm clinical study of the efficacy of orelabrutinib and lenalidomide (O-R regimen) in maintenance therapy in patients with highly aggressive B cell lymphoma (China)